{"product_id":"tirzepatide-10mg-lyophilized-powder-dual-agonist-gip-glp-1","title":"Tirzepatide (Mounjaro) · 10mg","description":"\u003cp\u003e\u003cstrong\u003eTirzepatide\u003c\/strong\u003e is a novel dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist designed as a single synthetic peptide. It acts on both incretin receptors simultaneously, demonstrating superior glycaemic control and body weight reduction compared to GLP-1 mono-agonists in research models. Studied extensively in metabolic research, obesity biology, insulin sensitivity modulation, and pancreatic beta-cell function.\u003c\/p\u003e\u003cp\u003eSynthesised and lyophilised in Zürich to \u0026gt;99% HPLC purity. Lot-traceable with full COA available upon request.\u003c\/p\u003e\u003cdetails\u003e\u003csummary\u003e\u003cstrong\u003eTechnical Specifications\u003c\/strong\u003e\u003c\/summary\u003e\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eChemical Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTirzepatide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCAS Number\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023788-19-2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMolecular Formula\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eC225H348N48O68\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e4813.6 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eReceptor Targets\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGIP receptor (GIPR) and GLP-1 receptor (GLP-1R)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99% (HPLC-UV)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLyophilised Powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e-20C, protect from light and moisture\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBacteriostatic water or sterile saline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003c\/details\u003e\u003cdetails\u003e\u003csummary\u003e\u003cstrong\u003eResearch \u0026amp; Literature\u003c\/strong\u003e\u003c\/summary\u003e\u003cp\u003eTirzepatide was developed as a novel dual GIP\/GLP-1 receptor agonist. Key clinical studies include the SURPASS clinical trial program, which demonstrated superior HbA1c reduction and body weight loss compared to GLP-1 receptor agonists alone. Research by Frias et al. (2021) in The Lancet reported significant glycaemic improvements in type 2 diabetes patients. Preclinical studies have also explored its role in beta-cell preservation and insulin sensitivity modulation.\u003c\/p\u003e\u003c\/details\u003e\u003cp\u003e\u003cem\u003eFor research purposes only. Not for human consumption. Supplied in accordance with EU Regulation (EC) No 1907\/2006 (REACH) for research and analytical use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Zürich BioGenix","offers":[{"title":"Default Title","offer_id":53775896936785,"sku":null,"price":109.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1039\/8718\/3953\/files\/IMG-4559.png?v=1779824611","url":"https:\/\/zurichbiogenix.com\/products\/tirzepatide-10mg-lyophilized-powder-dual-agonist-gip-glp-1","provider":"Zürich BioGenix","version":"1.0","type":"link"}